Replies to post #76098 on Biotech Values

[DewDiligence]

GILD Dumps ACH-1095—ACHN Stunned

The zinger is buried within the PR for the 1Q09 financial results:

http://finance.yahoo.com/news/Achillion-Reports-First-pz-15255653.html

Achillion and Gilead have arrived at different opinions on the appropriate further progression of ACH-1095 [a/k/a/ GS 9525], based on their respective scientific assessments of the therapeutic index for ACH-1095 from various preclinical studies. Gilead indicated that it does not intend to initiate clinical development of GS 9525, while Achillion believes that the compound should be advanced.

As of 3/3/109, ACHN had $27.1M of cash; it looks like they will need all of it.